A new study shows that prices for 19 brand-name dermatology meds, including two from Valeant Pharmaceuticals, have increased almost fivefold, on average, over the past 6 years.
Last month, Alphabet, née Google, said that it would give its new businesses plenty of breathing room as part of its reorganization, allowing startups including its Life Sciences division the freedom to operate more independently. But Alphabet also wants to make sure that its fledgling companies can bear the load themselves, so it's offering them a lesson in fiscal management.
Turing Pharmaceuticals promised to lower the price of its toxoplasmosis med, Daraprim, in response to growing backlash from lawmakers and the public after it bought the drug in August and jacked up its price by more than 5000%. Now the company is opting to negotiate discounts with hospitals rather than cut the drug's list price.
In its second fiscal quarter, announced before the market opened on November 24, Patterson's animal health unit recorded revenues of $774.5 million--more than doubling its results from the same period a year ago.
Obesity treatment devices have been in the regulatory spotlight in 2015 with two approvals for balloon-based devices and another for a neurostimulator. That makes for a total of 5 FDA-approved obesity devices--including the two banding devices that were already approved.
Jaguar Animal Health held an Analyst and Investor Day in New York City on Nov. 16--its first since its May IPO. But the event didn't seem to turn around the tough reception Jaguar has received on Wall Street to date. By the end of trading on Friday, shares were down about 11% from their Monday opening price of $2.60.
Mallinckrodt's shares have suffered since short seller Citron Research called out the company's pricing policies and marketing efforts last week. A newly disclosed price hike set off a storm of criticism earlier this week. Now, the company is seeking to gin up shareholder support with a $500 million boost to its stock-buyback program.
Crossover investor Deerfield Management has joined the syndicate of Fractyl Laboratories with a $17 million addition to a Series C financing to bring it up to a total of $57 million. The startup will use the cash to continue backing clinical testing of its Revita Duodenal Mucosal Resurfacing System, which has already started an international multicenter trial and is slated to begin randomized studies in 2016.
Reimbursement for sacroiliac joint fusion as a treatment for some kinds of lower back pain is becoming more common after it gained a reimbursement code at the start of this year, despite the procedure remaining somewhat controversial.
Healthcare IT outfit Molecular Health raked in €25 million ($26.6 million) in financing to spur commercialization for its healthcare informatics platform, giving the company a boost as it charges ahead with product development and expands its global footprint.